Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. - Wikidata - awgldk - TriplyDB

Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.

Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.

http://www.wikidata.org/entity/Q39224943

about

Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy Understanding and altering cell tropism of vesicular stomatitis virus Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy High basal expression of interferon-stimulated genes in human bronchial epithelial (BEAS-2B) cells contributes to influenza A virus resistance Oncolytic immunotherapy: where are we clinically?Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells RIG-I is required for VSV-induced cytokine production by murine glia and acts in combination with DAI to initiate responses to HSV-1.Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1 Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression.Oncolytic vaccinia virotherapy for endometrial cancer Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.Oncolytic Immunotherapy for Treatment of Cancer.Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.Vesiculovirus neutralization by natural IgM and complement.Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy.Panorama from the oncolytic virotherapy summit.Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.Immune Consequences of in vitro Infection of Human Peripheral Blood Leukocytes with Vesicular Stomatitis Virus.Histone H1 depletion triggers an interferon response in cancer cells via activation of heterochromatic repeats.Tumor Restrictions to Oncolytic Virus.The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies.Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.APOBEC3 Mediates Resistance to Oncolytic Viral Therapy

P2860

Q26739777-0270F569-8E0D-4998-A575-7ACEE56978E8 Q26767209-41D44293-7F94-40C1-B0FD-B267E2E35B7C Q27687067-F711C49B-A933-4ED9-94D5-952B946B0215 Q28083766-DF15FC41-1F7C-4B49-87C9-CC1E6613A607 Q34337520-1555221E-3971-4D30-B798-5F46F807AB5E Q34405325-BDB373A6-B003-4D51-B908-C613600E36EA Q34656877-EF4EFF2B-0458-427E-95DC-6BEDF52FA129 Q35641491-B90A8096-B059-48B6-BBD8-EAB41CE19A30 Q35861186-59052F29-5916-4A93-A4E9-6DBE09E0A830 Q35893563-4FCA73EC-2D7F-4FBA-9F18-690F17A97109 Q36145522-3EE2BFEE-695B-4138-B294-B95F26296659 Q36202610-42F485D6-1701-40AC-A401-82512EE530C4 Q36257430-BA0B4119-9C27-4A32-AC63-C20EE808CC0A Q36682298-B9141F95-7D09-4AF5-963D-7BA3B9E23D44 Q37076976-1AFAF843-96CD-4916-8057-41F24FACEB45 Q37123143-5D0A0B7A-2865-452C-9626-8DAB4A6F7FFD Q37292354-53B7967B-AA91-4505-8B8D-B3C8C9160BFB Q37625385-9823E526-06D7-4868-A91C-E5F07CDF4630 Q37641644-2026773B-8F0B-4471-9ECD-04D46A6E6FC1 Q37646792-D74CB8A3-D123-4456-9B9A-70FC60D2CDC8 Q37681801-C75BD557-23EF-40B9-A6AB-EE4304B7590A Q37688850-8581E32F-079B-46D4-AE3B-0638A9BBF153 Q38221692-5120625B-FFD6-4F05-987D-DB3A410AA9E4 Q38223419-F81DFBBC-6D9E-48B4-9867-F94A96EDD507 Q38676507-E090B161-BDBE-4697-9A71-7458D0A9FBD7 Q38793802-4B50371A-0CEB-4316-93B5-B8386C525CB1 Q38848223-34FE50E9-37BF-439F-9F55-410D350737ED Q38860227-0DFB821A-A5B1-454B-8921-A27086B15772 Q38955561-124EDE7D-D98F-4B55-AE4B-BC159522DE87 Q39013686-4BA3A87E-F055-47F7-83BA-659F3761B71E Q39096636-5842D351-BAF7-4E00-BDCC-D109503C669C Q39109430-770632FC-884E-4D33-BACC-3166CE003866 Q42934744-69EF1853-BB58-4C8B-8B9A-4DF9F15DB041 Q45324769-23517E55-F7B0-4D41-8C1E-95FEF0BF5DE5 Q47557500-8D96D4FA-2670-47B5-9DD1-73C91A0B6D0C Q47700338-E64812FC-FF77-42EC-ABAC-78FE1B0D9E76 Q51846287-55C44EA5-D696-4737-9B8C-263D97AAAFAE Q52769266-2BA91F03-E7CD-46B0-87B7-B328A299C6BC Q54202657-BC737A4F-5CFF-4F31-A554-8D02DC7BA991 Q57192791-EC09D0E7-E595-4A47-9F67-DA12F6E42464

P2860

Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.

http://www.wikidata.org/entity/Q39224943

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Resistance of pancreatic cance ...... f type I interferon signaling.

@en

Resistance of pancreatic cance ...... f type I interferon signaling.

@nl

type

label

Resistance of pancreatic cance ...... f type I interferon signaling.

@en

Resistance of pancreatic cance ...... f type I interferon signaling.

@nl

prefLabel

Resistance of pancreatic cance ...... f type I interferon signaling.

@en

Resistance of pancreatic cance ...... f type I interferon signaling.

@nl

P1433

Q39224943-70926F69-9B02-4CB0-94AF-B030EACAA11C

P1476

Q39224943-5BEEA220-6B47-41AB-B1D6-1F129AFB5158

P2093

Q39224943-02D42E8D-2E2A-4DA6-AA1F-5D68D60AA2BE

Q39224943-31BF7F1E-1FA5-4640-9BA0-027E62530C1D

Q39224943-92EC4D8C-FD27-4349-A996-227A7D01DC31

Q39224943-995E8C8F-D9E5-4460-AFD6-3BE5F32EE9A6

Q39224943-B5C039B9-5D6D-4060-B511-7352D96D2359

Q39224943-CC1D64FB-4D69-4A66-8BBE-25AD273DB15A

P2860

Q39224943-0225183B-47F1-441D-ACDE-7FADFC958CD0

Q39224943-030A34C5-0466-46B7-A201-F3FAE5BE9657

Q39224943-0C61A48E-99A4-4419-885A-EAFF168053A7

Q39224943-13C10E96-2E0C-4856-B411-FB76196A6859

Q39224943-1D2AF2DF-1F34-410A-BA59-1E0F9DC95838

Q39224943-22C0498F-BF8D-40C2-8F77-412430B5AACF

Q39224943-263F4F9F-0467-4A36-A8FB-4A53D9AA6DBB

Q39224943-26BE1033-6AD8-4B0D-AAFC-5437E0C97255

Q39224943-26ED6BEB-C787-4332-A8E7-9A964B6ABA97

Q39224943-281BACB7-B02B-4AF6-966E-99AC014A729D

P304

Q39224943-5FD89219-901D-4214-864B-304B89CF90DD

P31

Q39224943-5F8B95F2-F4B2-4FE1-871D-985819E4F16B

P356

Q39224943-779881A9-D445-46E6-8438-525CADB704A5

P407

Q39224943-CEDE1745-1ED1-4472-9972-AF0F882ECE02

P433

Q39224943-E2CA0781-EB62-4905-9F59-95A481286B01

P478

Q39224943-70CA7A92-1312-4C74-A0A2-9641377B3D07

P577

Q39224943-32DD052C-DAB0-410E-B8B2-1A3A914763F5

P5875

Q39224943-42DD0A7E-9EE6-4BD4-8A26-C1BCF73F08A8

P698

Q39224943-5D1D2034-FE40-4E57-870B-2831E17E2A73

P921

Q39224943-5A19E6C5-5591-4808-8975-E7A625A46806

P932

Q39224943-424F0DD0-D4AC-4E14-8A5D-A00BD1E70C39

P356

J.VIROL.2012.11.014

P1433

P1476

Resistance of pancreatic cance ...... f type I interferon signaling.

@en

P2093

Andrea M Murphy

http://www.w3.org/2001/XMLSchema#string

Eric Hastie

http://www.w3.org/2001/XMLSchema#string

Megan Moerdyk-Schauwecker

http://www.w3.org/2001/XMLSchema#string

Nirav R Shah

http://www.w3.org/2001/XMLSchema#string

Pinku Mukherjee

http://www.w3.org/2001/XMLSchema#string

Valery Z Grdzelishvili

http://www.w3.org/2001/XMLSchema#string

P2860

Intelligent design: combination therapy with oncolytic viruses

MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer

Interferon-inducible antiviral effectors

Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase

VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway

IRF-7 is the master regulator of type-I interferon-dependent immune responses

Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting.

Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.

Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways.

P304

221-234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VIROL.2012.11.014

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

436

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233940386

http://www.w3.org/2001/XMLSchema#string

P698

23246628

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3544977

http://www.w3.org/2001/XMLSchema#string